Pediatric Drugs

, Volume 21, Issue 2, pp 71–79 | Cite as

Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma

  • Haya S. Raef
  • Alison M. Friedmann
  • Elena B. HawrylukEmail author
Review Article


Although melanoma is a rare diagnosis in the pediatric population, advances in the management of adults with melanoma offer the prospect of promising therapeutic options for children. At this time, medical management is not considered curative but may reduce the risk of recurrence or prolong survival. Surgical management remains the mainstay of treatment. Medical therapy of pediatric melanoma is not thought to have a role for in situ, early-stage, or localized disease, but adjuvant therapy may have a role in improving the prognosis of patients with positive sentinel lymph node biopsy (SLNB), spread beyond the regional lymph node basin, metastatic disease, or recurrent disease. Medical treatment options include immunotherapies, particularly checkpoint inhibitors, and targeted therapies, which have provided improved toxicity profiles compared with traditional chemotherapy regimens in the setting of advanced disease. There is a growing body of pediatric-specific data relevant to the use of adjuvant therapies for advanced melanoma in children.


Compliance with Ethical Standards


This work was funded by the Dermatology Foundation and the Society for Pediatric Dermatology (EBH).

Conflicts of Interest

Elena B. Hawryluk’s spouse has received stock from Foundation Medicine Inc. and salary and stock from Gritstone Oncology. Elena B. Hawryluk has received authorship honorarium from UpToDate, Inc. Haya S. Raef and Alison M. Friedmann, MD, MSc, have no conflicts of interest that might be relevant to the contents of this manuscript.


  1. 1.
    U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999–2015): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute;, June 2018.
  2. 2.
    Austin MT, et al. Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg. 2013;48(11):2207–13.Google Scholar
  3. 3.
    Campbell LB, et al. Melanoma incidence in children and adolescents: decreasing trends in the United States. J Pediatr. 2015;166(6):1505–13.Google Scholar
  4. 4.
    Strouse JJ, et al. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23(21):4735–41.Google Scholar
  5. 5.
    Lange JR, et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007;25(11):1363–8.Google Scholar
  6. 6.
    Krengel S, Hauschild A, Schäfer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006;155(1):1–8.Google Scholar
  7. 7.
    Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39(18):2651–61.Google Scholar
  8. 8.
    Ward EM, et al. Industries and cancer. Cancer Causes Control. 1997;8(3):356–70.Google Scholar
  9. 9.
    Paradela S, et al. Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 patients. Cancer. 2010;116(18):4334–44.Google Scholar
  10. 10.
    Bartenstein DW, et al. Contrasting features of childhood and adolescent melanomas. Pediatr Dermatol. 2018;35(3):354–60.Google Scholar
  11. 11.
    Cordoro KM, et al. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol. 2013;68(6):913–25.Google Scholar
  12. 12.
    Pappo AS. Pediatric melanoma: the whole (genome) story. Am Soc Clin Oncol Educ Book. 2014; p. e432-34355.Google Scholar
  13. 13.
    Barnhill R, et al. Malignant Spitz tumor and Spitz Naevus. In: Elder DE, Massi D, Scolyer R, Willemze R, editors. WHO classification of tumours, Fourth edition. Geneva: International Agency for Research on Cancer; 2018. pp. 46–51.Google Scholar
  14. 14.
    Paradela S, et al. Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J Cutan Pathol. 2009;36(7):740–52.Google Scholar
  15. 15.
    Celebi JT, Messina JL. Challenging melanocytic neoplasms: spitzoid melanoma vs. spitz nevus. Melanoma: Translational Research and Emerging Therapies, 2008; p. 27.Google Scholar
  16. 16.
    Vourc’h-Jourdain M, Martin L, Barbarot S. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol. 2013;68(3):493–498. e14.Google Scholar
  17. 17.
    Bett BJ. Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. J Am Acad Dermatol. 2005;52(5):793–7.Google Scholar
  18. 18.
    Bahrami A, Barnhill RL. Pathology and genomics of pediatric melanoma: a critical reexamination and new insights. Pediatr Blood Cancer. 2018;65(2):e26792.Google Scholar
  19. 19.
    Lu C, et al. The genomic landscape of childhood and adolescent melanoma. J Investig Dermatol. 2015;135(3):816–23.Google Scholar
  20. 20.
    Hodis E, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251–63.Google Scholar
  21. 21.
    Kim J, et al. Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma. J Pediatr Surg. 2016;51(6):986–90.Google Scholar
  22. 22.
    Faries MB, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.Google Scholar
  23. 23.
    Palmer PE, et al. Complications in the surgical treatment of pediatric melanoma. J Pediatr Surg. 2013;48(6):1249–53.Google Scholar
  24. 24.
    Wrightson WR, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10(6):676–80.Google Scholar
  25. 25.
    Kirkwood JM, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.Google Scholar
  26. 26.
    Kirkwood JM, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.Google Scholar
  27. 27.
    Kirkwood JM, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.Google Scholar
  28. 28.
    Mocellin S, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.Google Scholar
  29. 29.
    Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998–1012.Google Scholar
  30. 30.
    Cormier JN, et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007;25(17):2442–8.Google Scholar
  31. 31.
    Messori A, et al. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer. 1997;33(9):1373–9.Google Scholar
  32. 32.
    Navid F, et al. Feasibility of pegylated interferon in children and young adults with resected high-risk melanoma. Pediatr Blood Cancer. 2016;63(7):1207–13.Google Scholar
  33. 33.
    Navid F, et al. The feasibility of adjuvant interferon α-2b in children with high-risk melanoma. Cancer. 2005;103(4):780–7.Google Scholar
  34. 34.
    Chao MM, et al. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer. 2005;44(5):441–8.Google Scholar
  35. 35.
    Shah NC, et al. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. J Pediatr Hematol Oncol. 2006;28(8):496–500.Google Scholar
  36. 36.
    He X-H, Shaw P-C, Tam S-C. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 1999;65(4):355–68.Google Scholar
  37. 37.
    Glue P, et al. Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Therap. 2000;68(5):556–67.Google Scholar
  38. 38.
    Eggermont AM, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. The Lancet. 2008;372(9633):117–26.Google Scholar
  39. 39.
    Lindsay KL, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395–403.Google Scholar
  40. 40.
    Bukowski RM, et al. Treating cancer with PEG intron. Cancer. 2002;95(2):389–96.Google Scholar
  41. 41. Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma. 2017; Available from:
  42. 42.
    Rosenberg SA et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI J Natl Cancer Inst 1993;85(8):622–632.Google Scholar
  43. 43.
    Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–2105.Google Scholar
  44. 44.
    Ribeiro RC, et al. Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer. 1993;72(2):623–8.Google Scholar
  45. 45.
    Bauer M, et al. A phase II trial of human recombinant lnterleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin’s lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study. Cancer. 1995;75(12):2959–65.Google Scholar
  46. 46.
    Yamane BH et al. The development of antibody-IL-2 based immunotherapy with hu14. 18-IL2 (EMD-273063) in melanoma and neuroblastoma. Exp Opin Investig Drugs 2009;18(7):991–1000.Google Scholar
  47. 47.
    Osenga KL et al. A phase I clinical trial of the hu14. 18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children’s Oncology Group. Clin Cancer Res 2006;12(6):1750–1759.Google Scholar
  48. 48.
    Eggermont AM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.Google Scholar
  49. 49.
    Merchant M et al. Phase 1 clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res 2015;p. clincanres. 0491.2015.Google Scholar
  50. 50.
    Geoerger B, et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017;86:358–63.Google Scholar
  51. 51.
    Topalian SL, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.Google Scholar
  52. 52.
    Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.Google Scholar
  53. 53.
    Davis KL et al. ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study. 2017, American Society of Clinical Oncology.Google Scholar
  54. 54.
    Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014;384(9948):1109–17.Google Scholar
  55. 55.
    Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.Google Scholar
  56. 56., A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051). 2018. Available from:
  57. 57.
    Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. The Lancet. 2014;383(9919):816–27.Google Scholar
  58. 58.
    Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949.Google Scholar
  59. 59.
    Pollock PM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2002;33(1):19.Google Scholar
  60. 60.
    Curtin JA, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47.Google Scholar
  61. 61.
    Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.Google Scholar
  62. 62.
    Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772–4.Google Scholar
  63. 63.
    Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.Google Scholar
  64. 64.
    Carnahan J, et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Therap. 2010;9(8):2399–410.Google Scholar
  65. 65.
    Robert C, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.Google Scholar
  66. 66.
    Wing EJ, et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood. 1989;73(3):643–6.Google Scholar
  67. 67.
    Hayes FA, Green AA. Malignant melanoma in childhood: clinical course and response to chemotherapy. J Clin Oncol. 1984;2(11):1229–34.Google Scholar
  68. 68.
    Boddie AW, Cangir A. Adjuvant and neoadjuvant chemotherapy with dacarbazine in high-risk childhood melanoma. Cancer. 1987;60(8):1720–3.Google Scholar
  69. 69.
    Peter C, et al. Hyperthermic isolated regional perfusion in the treatment of extremity melanoma in children and adolescents. Cancer. 1989;63:199–203.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Tufts University School of MedicineBostonUSA
  2. 2.School of MedicineHarvard UniversityBostonUSA
  3. 3.Department of PediatricsMassachusetts General HospitalBostonUSA
  4. 4.Department of DermatologyMassachusetts General HospitalBostonUSA
  5. 5.Dermatology Program, Division of Immunology, Department of MedicineBoston Children’s HospitalBostonUSA

Personalised recommendations